

## **SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Lasea, soft capsules

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

1 soft capsule contains:

80 mg *Lavandula angustifolia* Miller, aetheroleum (lavender oil).

Excipient with known effect: Sorbitol, app. 12 mg/soft capsule.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Soft capsule

Oval transparent colourless soft capsule.

Capsule dimensions: length approx. 11 mm, width approx. 7 mm.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Traditional herbal medicinal product for relief of mild anxiety and to aid sleep.

The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

Lasea is indicated in adults and adolescents from 12 years of age.

### **4.2 Posology and method of administration**

#### Posology

Adults and adolescents from 12 years of age take one soft capsule once daily (corresponding to 80 mg lavender oil per day).

#### *Paediatric population*

Lasea should not be used in children under the age of 12 years (see section 4.4 'Special warnings and precautions for use').

#### Method of administration

Oral use. The soft capsules are to be swallowed whole with sufficient liquid (preferably a glass of water).

#### Duration of use

If the symptoms persist after two weeks use of the product, a doctor or a qualified health care practitioner should be consulted.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

#### **4.4 Special warnings and precautions for use**

The use in children under 12 years of age has not been established due to lack of adequate data.

If the symptoms worsen during the use of the product, a doctor or a qualified health care practitioner should be consulted.

The use in patients with impairment of hepatic function is not recommended as components of lavender oil are largely eliminated by metabolism in the liver.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Published data show that lavender oil (160 mg/day) has no clinically relevant inhibitory or inducing effects on the CYP 1A2, 2C9, 2C19, 2D6 and 3A4 enzymes in human. In addition, no relevant clinical impact of lavender oil on the contraceptive efficacy of combined oral contraceptive was found.

#### **4.6 Fertility, pregnancy and lactation**

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Data on fertility are not available.

#### **4.7 Effects on ability to drive and use machines**

Lasea has no or negligible influence on the ability to drive and use machines.

#### **4.8 Undesirable effects**

##### Gastrointestinal disorders

Mild gastrointestinal complaints (e.g. eructation). The frequency is not known.

##### Skin and subcutaneous tissue disorders / Immune system disorders

Hypersensitivity reactions. The frequency is not known.

##### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the safety of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in ...[To be completed nationally]

#### **4.9 Overdose**

No case of overdose has been reported.

### **5. PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

-

#### **5.2 Pharmacokinetic properties**

-

#### **5.3 Preclinical safety data**

In vitro and in vivo genotoxicity tests performed with lavender oil contained in Lasea, soft capsule did not show any genotoxic potential. Adequate tests on carcinogenicity and reproductive toxicity of lavender oil have not been performed.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Capsule content:  
refined rapeseed oil

Capsule shell:  
gelatin succinylated  
glycerol 85%  
sorbitol 70%, non crystallising

### **6.2 Incompatibilities**

None known

### **6.3 Shelf life**

5 years

### **6.4 Special precautions for storage**

Do not store at temperatures above 30 °C.

### **6.5 Nature and contents of container**

The container (blister) is made of PVC/PVDC/Al foil.  
Packs with 14, 28 and 56 soft capsules.  
Not all pack sizes may be marketed.

### **6.6 Special precautions for disposal and other handling**

No special requirements

## **7. REGISTRATION HOLDER**

Dr. Willmar Schwabe GmbH & Co. KG  
Willmar-Schwabe-Str. 4  
76227 Karlsruhe  
Germany

## **8. REGISTRATION NUMBER(S)**

<[To be completed nationally]>

**9. DATE OF FIRST REGISTRATION/RENEWAL OF THE REGISTRATION**

Date of first registration: 09 June 2016

Date of renewal: 19 February 2021

**10. DATE OF REVISION OF THE TEXT**

28 March 2025